Biotechnology in the Netherlands

Introduction

Biotechnology in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Netherlands biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates.

*The Dutch biotechnology market had total revenue of $340.1 million in 2010, representing a compound annual growth rate (CAGR) of 5.2% between 2006 and 2010.

*Medical/Healthcare sales proved the most lucrative for the Dutch biotechnology market in 2010, with total revenues of $261.6 million, equivalent to 76.9% of the market's overall value.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 5.4% for the five-year period 2010 - 2015, which is expected to drive the market to a value of $441.4 million by the end of 2015.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the Netherlands

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the Netherlands

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Netherlands economy

Key Questions Answered

What was the size of the Netherlands biotechnology market by value in 2010?

What will be the size of the Netherlands biotechnology market in 2015?

What factors are affecting the strength of competition in the Netherlands biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up the Netherlands's biotechnology market?
[Studien Infos ausblenden]

TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
FIVE FORCES ANALYSIS 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
LEADING COMPANIES 19
Actelion 19
Astra Zeneca 23
Biogen Idec (Avonex) 27
Crucell NV 30
MARKET FORECASTS 34
Market value forecast 34
MACROECONOMIC INDICATORS 35
APPENDIX 37
Methodology 37
Industry associations 38
Related Datamonitor research 38
Disclaimer 39
ABOUT DATAMONITOR 40
Premium Reports 40
Summary Reports 40
Datamonitor consulting 40

LIST OF TABLES
Table 1: Netherlands biotechnology market value: $ million, 2006–10 10
Table 2: Netherlands biotechnology market segmentation I:% share, by value, 2010 11
Table 3: Netherlands biotechnology market segmentation II: % share, by value, 2010 12
Table 4: Actelion: key facts 19
Table 5: Actelion: key financials ($) 20
Table 6: Actelion: key financials (CHF) 21
Table 7: Actelion: key financial ratios 21
Table 8: Astra Zeneca: key facts 23
Table 9: Astra Zeneca: key financials ($) 25
Table 10: Astra Zeneca: key financial ratios 25
Table 11: Biogen Idec (Avonex): key facts 27
Table 12: Biogen Idec (Avonex): key financials ($) 28
Table 13: Biogen Idec (Avonex): key financial ratios 28
Table 14: Crucell NV: key facts 30
Table 15: Crucell NV: key financials ($) 31
Table 16: Crucell NV: key financials (€) 31
Table 17: Crucell NV: key financial ratios 32
Table 18: Netherlands biotechnology market value forecast: $ million, 2010–15 34
Table 19: Netherlands size of population (million), 2006–10 35
Table 20: Netherlands gdp (constant 2000 prices, $ billion), 2006–10 35
Table 21: Netherlands gdp (current prices, $ billion), 2006–10 35
Table 22: Netherlands inflation, 2006–10 36
Table 23: Netherlands consumer price index (absolute), 2006–10 36
Table 24: Netherlands exchange rate, 2006–10 36

LIST OF FIGURES
Figure 1: Netherlands biotechnology market value: $ million, 2006–10 10
Figure 2: Netherlands biotechnology market segmentation I:% share, by value, 2010 11
Figure 3: Netherlands biotechnology market segmentation II: % share, by value, 2010 12
Figure 4: Forces driving competition in the biotechnology market in the Netherlands, 2010 13
Figure 5: Drivers of buyer power in the biotechnology market in the Netherlands, 2010 14
Figure 6: Drivers of supplier power in the biotechnology market in the Netherlands, 2010 15
Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in the Netherlands, 2010 16
Figure 8: Factors influencing the threat of substitutes in the biotechnology market in the Netherlands, 2010 17
Figure 9: Drivers of degree of rivalry in the biotechnology market in the Netherlands, 2010 18
Figure 10: Actelion: revenues & profitability 22
Figure 11: Actelion: assets & liabilities 22
Figure 12: Astra Zeneca: revenues & profitability 26
Figure 13: Astra Zeneca: assets & liabilities 26
Figure 14: Biogen Idec (Avonex): revenues & profitability 29
Figure 15: Crucell NV: revenues & profitability 32
Figure 16: Crucell NV: assets & liabilities 33
Figure 17: Netherlands biotechnology market value forecast: $ million, 2010–15 34


[Inhaltsverzeichnis ausblenden]